Zymeworks reports 44% reduction in nine-month net loss to $104.2M; launches ZW251 IND candidate for HCC

Zymeworks Inc.

2023-Q3 EPS reported -$1.53 revenue$59,086,000

Nine-month net loss decreased 44% to $104.2M vs $185.1M same period 2022; revenue up 491% to $59.1M.
Cash resources $390.2M as of Sept 30, 2023; expected to fund operations through at least end of 2026.
ZW251, GPC3-targeted ADC for hepatocellular carcinoma, nominated as next IND candidate; filing expected 2H-2025.
Zanidatamab partner BeiGene presented Phase 1b/2 data: ORR 75.8%, mDOR 22.8 months, mPFS 16.7 months in first-line HER2+ GEA.
Termination of licensing agreement for zanidatamab zovodotin with BeiGene; Zymeworks regained APAC rights and plans Phase 2 study in NSCLC.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Zymeworks Inc. reported financial results for third quarter 2023.

Period: third quarter 2023
Result: reported results

Exact text from the filing

On November 7, 2023 , Zymeworks Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2023.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Zymeworks Inc. filing history →

Source: SEC EDGAR

accession 0001937653-23-000036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.